Pancreatic Ductal Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PNC013 MIFTS: 47	Pancreatic Ductal Carcinoma Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma ¹² ¹⁵

Carcinoma, Pancreatic Ductal ⁴⁴ ⁷³

Malignant Neoplasm of Duct of Wirsung ¹²

Carcinoma Pancreatic Ductal ⁵⁵

Pancreatic Duct Cancer ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of pancreas

Malignant neoplasm: Pancreatic duct

External Ids:

Disease Ontology ¹² DOID:3587

ICD10 ³³ C25.3

ICD9CM ³⁵ 157.3

MeSH ⁴⁴ D021441

SNOMED-CT ⁶⁸ 93939009

UMLS ⁷³ C0153461 C0887833

Sources

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : ¹² A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to microcystic adenoma and cystadenocarcinoma. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Paclitaxel and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and ovary, and related phenotypes are cellular and neoplasm

Sources

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)

#	Related Disease	Score	Top Affiliating Genes
1	microcystic adenoma	30.3	MUC1 MUC6
2	cystadenocarcinoma	29.6	KRT7 MUC1 MUC2 TP53 VEGFA
3	adenocarcinoma	29.1	CDKN2A MUC1 SMAD4 TP53 VEGFA
4	pancreatic cancer	28.9	CDKN2A MUC1 MUC2 SMAD4 TP53 VEGFA
5	pancreatic adenosquamous carcinoma	11.3
6	nodular hidradenoma	10.3	KRT7 MUC1
7	parachordoma	10.3	KRT7 MUC1
8	sertoli-leydig cell tumor	10.3	KRT7 MUC1
9	mucinous ovarian cystadenoma	10.3	KRT7 MUC1
10	hidradenoma	10.3	KRT7 MUC1
11	spindle cell sarcoma	10.3	KRT7 MUC1
12	secretory meningioma	10.3	KRT7 MUC1
13	sclerosing hemangioma	10.3	KRT7 MUC1
14	middle ear adenoma	10.3	KRT7 MUC1
15	lipoadenoma	10.3	KRT7 MUC1
16	monophasic synovial sarcoma	10.3	KRT7 MUC1
17	meconium ileus	10.3	MUC1 MUC2
18	epithelioid hemangioendothelioma	10.3	MUC1 VEGFA
19	pancreatic serous cystadenoma	10.3	KRT7 VEGFA
20	superior mesenteric artery syndrome	10.3	MUC2 MUC6
21	brachydactyly, type e1	10.3	KRT20 MUC1
22	villous adenoma	10.3	KRT20 MUC1
23	dendritic cell tumor	10.2	KRT20 MUC1
24	jejunal adenocarcinoma	10.2	KRT20 KRT7
25	immune system organ benign neoplasm	10.2	KRT20 KRT7
26	bladder lymphoma	10.2	KRT20 KRT7
27	chronic cystitis	10.2	KRT20 KRT7
28	thymus lipoma	10.2	KRT20 KRT7
29	rectum adenocarcinoma	10.2	KRT20 KRT7
30	prostatic acinar adenocarcinoma	10.2	KRT20 KRT7
31	bladder adenocarcinoma	10.2	KRT20 KRT7
32	linitis plastica	10.2	KRT20 KRT7
33	infiltrative basal cell carcinoma	10.2	KRT20 KRT7
34	medulloepithelioma	10.2	KRT20 KRT7
35	thymus adenocarcinoma	10.2	KRT20 KRT7
36	ovarian cystic teratoma	10.2	KRT20 KRT7
37	adenoid squamous cell carcinoma	10.2	KRT20 KRT7
38	gastric diffuse adenocarcinoma	10.2	KRT20 KRT7
39	lung acinar adenocarcinoma	10.2	KRT20 KRT7
40	intratubular embryonal carcinoma	10.2	KRT20 KRT7
41	horseshoe kidney	10.2	KRT20 KRT7
42	small cell carcinoma of the bladder	10.2	KRT20 KRT7
43	meibomian cyst	10.2	KRT20 KRT7
44	chronic myocardial ischemia	10.2	TYMP VEGFA
45	papilloma of choroid plexus	10.2	MUC1 TP53
46	chordoid glioma	10.2	MUC1 TP53
47	cerebral primitive neuroectodermal tumor	10.2	MUC1 TP53
48	prostate squamous cell carcinoma	10.2	KRT7 TP53
49	mixed cell type cancer	10.2	KRT7 TP53
50	female reproductive endometrioid cancer	10.2	KRT7 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:

Sources

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.56	CDKN2A KRT7 MUC2 SMAD4 TGM2 TP53
2	neoplasm	MP:0002006	9.1	CDKN2A MUC2 SMAD4 TGM2 TP53 VEGFA

Sources

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 1,Phase 2

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DFDC

2',2'-DiF-dC

2',2'-difluoro-2'-Deoxycytidine

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate

2'-Deoxy-2'-difluorocytidine

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFdC

DFDC

DFdCyd

Folfugem

Gamcitabine

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

gemcitabine

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer

Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Gemcitabine, (D-threo-pentafuranosyl)-isomer

Gemcitabinum

Gemcitabinum [INN-Latin]

GemLip

Gemtro

Gemzar

Gemzar (hydrochloride)

GEO

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY188011

LY-188011

NCGC00168784-01

NChemBio.2007.10-comp25

nchembio.573-comp7

nchembio.90-comp2

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

Zefei

ZINC18279854

Hyaluronic acid

Approved, Vet_approved

Phase 3

9004-61-9

53477741

Antiviral Agents

Phase 3,Phase 1,Phase 2

Immunologic Factors

Phase 3,Phase 1,Phase 2

Immunosuppressive Agents

Phase 3,Phase 1,Phase 2

Antineoplastic Agents, Phytogenic

Phase 3,Phase 1,Phase 2

Antimetabolites, Antineoplastic

Phase 3,Phase 1,Phase 2

Antimetabolites

Phase 3,Phase 1,Phase 2

Anti-Infective Agents

Phase 3,Phase 1,Phase 2

Antimitotic Agents

Phase 3,Phase 1,Phase 2

Albumin-Bound Paclitaxel

Phase 3,Phase 1,Phase 2

Protective Agents

Phase 3

Adjuvants, Immunologic

Phase 3

acivicin

Phase 3

Viscosupplements

Phase 3

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-hydroxydaunomycin

14-Hydroxydaunomycin

14-hydroxydaunorubicine

14-Hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

adiblastine (hydrochloride salt)

ADM

ADR

adr iablatina (hydrochloride salt)

Adriablastin

Adriablastine

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin semiquinone

Adriamycin Semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (hydrochloride salt)

Adriblastina (TN)

Adriblastine

adriblatina (hydrochloride salt)

Adrimedac

Aerosolized Doxorubicin

Baxter brand OF doxorubicin hydrochloride

Bedford brand OF doxorubicin hydrochloride

BPBio1_000502

BRD-K92093830-003-04-3

Bristol-myers squibb brand OF doxorubicin hydrochloride

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

Caelyx

CCRIS 739

Cell pharm brand OF doxorubicin hydrochloride

CHEBI:28748

CHEMBL179

CID31703

Columbia brand OF doxorubicin hydrochloride

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

Doxil

Doxo

doxo Cell

doxo-Cell

Doxolem

doxorubicin

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin HCl

Doxorubicin hexal

Doxorubicin hydrochloride

Doxorubicin Hydrochloride

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin NC

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicina ferrer farm

Doxorubicina funk

Doxorubicina tedec

Doxorubicine

Doxorubicine [INN-French]

Doxorubicine baxter

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicinum

Doxorubicinum [INN-Latin]

Doxotec

DOX-SL

EINECS 245-495-6

Elan brand OF doxorubicin hydrochloride

Farmablastina (hydrochloride salt)

Farmiblastina

Ferrer brand OF doxorubicin hydrochloride

FI 106

Hexal brand OF doxorubicin hydrochloride

HMS2089H06

HSDB 3070

Hydrochloride, doxorubicin

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

Kenfarma brand OF doxorubicin hydrochloride

Lemery brand OF doxorubicin hydrochloride

LMPK13050001

LS-1029

LS-165655

Medac brand OF doxorubicin hydrochloride

MLS000759533

Myocet

NChemBio.2007.10-comp13

nchembio809-comp5

NCI-C01514

NDC 38242-874

Neocorp brand OF doxorubicin hydrochloride

NIOSH/JT9100000

NSC 123127

Onkodox

Onkoworks brand OF doxorubicin hydrochloride

Pfizer brand OF doxorubicin hydrochloride

Prasfarma brand OF doxorubicin hydrochloride

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Ribodoxo

Ribosepharm brand OF doxorubicin hydrochloride

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

Tedec meiji brand OF doxorubicin hydrochloride

ThermoDox

TLC D-99

Triferric doxorubicin

UNII-80168379AG

Urokit doxo cell

Urokit doxo-cell

Pancrelipase

Approved, Investigational

Phase 1, Phase 2

53608-75-6

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Synonyms:

(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

154361-50-9

158798-73-3

5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine

5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine

AC1L1U83

AC1Q4KU8

Ambap154361-50-9

C110904

C12650

C15H22FN3O6

CAPE

Capecitabin

capecitabina

Capecitabina

capecitabine

CAPECITABINE

Capécitabine

Capecitabine (JAN/USAN/INN)

Capecitabine [USAN]

capecitabinum

Capecitabinum

Capecitibine

Capiibine

Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester

Caxeta

CHEBI:31348

CHEMBL1773

CID60953

D01223

DB01101

FT-0082472

HSDB 7656

LS-59070

MolPort-005-938-254

N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine

Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

R340

R-340

RG-340

Ro 09-1978

Ro 09-1978/000

Ro-09-1978

Ro-09-1978/000

S1156_Selleck

UNII-6804DJ8Z9U

Xabine

Xeloda

Xeloda (TN)

Xeloda, Captabin, Capecitabine

ZINC03806413

Doxil

Approved June 1999

Phase 2

31703

Tremelimumab

Investigational

Phase 2

745013-59-6

Topoisomerase Inhibitors

Phase 2

Antibiotics, Antitubercular

Phase 2

Anti-Bacterial Agents

Phase 2

Immunoglobulins

Phase 1, Phase 2,Phase 2

Antibodies

Phase 1, Phase 2,Phase 2

Antibodies, Monoclonal

Phase 1, Phase 2,Phase 2

pancreatin

Phase 1, Phase 2

Cola

Phase 1, Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Recruiting	NCT02715804	Phase 3	Placebo;Nab-paclitaxel;Gemcitabine
2	Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer	Completed	NCT01580397	Phase 2	INNO-206
3	Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma	Completed	NCT02583477	Phase 1, Phase 2	MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
4	Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma	Completed	NCT02558894	Phase 2	MEDI4736 monotherapy;tremelimumab+MEDI4736
5	PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer	Completed	NCT01839487	Phase 2	PEGPH20+nab-paclitaxel+gemcitabine;nab-paclitaxel + gemcitabine
6	QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer	Completed	NCT01040000	Phase 1, Phase 2	NPC-1C/NEO-102
7	Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer	Terminated	NCT02243007	Phase 2	FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
8	A Dose-Finding Study of MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	Completed	NCT02259114	Phase 1	MK-8628

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

gemcitabine

gemcitabine hydrochloride

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Sources

Genetic Tests for Pancreatic Ductal Carcinoma

Sources

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

⁴¹

Pancreas, Lung, Ovary, Cervix, Thymus, Small Intestine, Appendix

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

¹⁹

The Pancreatic Duct

Sources

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 82)

#	Title	Authors	Year
1	Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. ( 29409514 )	Sonntag K....Schilbach K.	2018
2	Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. ( 30240298 )	Marion-Audibert AM...Rode A	2018
3	The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. ( 27458977 )	Long L.M....Liu Y.S.	2017
4	Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. ( 28099249 )		2017
5	Adjuvant treatment for pancreatic ductal carcinoma. ( 28639051 )		2017
6	Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation. ( 29273724 )		2017
7	Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. ( 28927124 )		2017
8	Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. ( 29254283 )	Wu Q...Wang D	2017
9	Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. ( 27552832 )	Dugnani E....Piemonti L.	2016
10	Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma. ( 27184637 )	Uekitani T....Sakaida I.	2016
11	A case report on metastatic pancreatic tumor from pulmonary adenocarcinoma that difficult to differentiate from primary pancreatic ductal carcinoma. ( 27498937 )	Takei D....Yonehara S.	2016
12	Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. ( 27237099 )	Ishida J....Ku Y.	2016
13	Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. ( 26261495 )	Zheng K.L....Zhang Y.J.	2015
14	Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. ( 24845232 )	Kaira K....Takeyoshi I.	2014
15	Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. ( 24901166 )	Kawada N....Tomita Y.	2014
16	Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. ( 24778053 )	Iida T...Yanaga K	2014
17	Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma. ( 23648465 )	Oguro S....Hiraoka N.	2013
18	Clinicopathologic assessment of pancreatic ductal carcinoma located at the head of the pancreas, in relation to embryonic development. ( 22228049 )	Okamura Y....Nakao A.	2012
19	Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. ( 22892044 )	Takadate T....Unno M.	2012
20	Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? ( 20579970 )		2012
21	Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. ( 21841817 )		2012
22	Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. ( 22190076 )		2012
23	Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. ( 22562451 )		2012
24	KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. ( 21224073 )	Zammarchi F....Mazzanti C.M.	2011
25	Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma. ( 20730891 )	Jarboe E.A....Layfield L.J.	2011
26	Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with I^-catenin in tumor progression. ( 21466814 )	Xu H....Kokudo N.	2011
27	Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. ( 21272935 )		2011
28	Asymptomatic curable pancreatic ductal carcinoma detected during the follow-up of pancreatic cysts distinct from carcinoma. ( 26190721 )	Kawada N...Ishikawa O	2011
29	Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ( 19856421 )	Han L....Feng J.	2010
30	Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. ( 18845377 )		2009
31	Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. ( 19248224 )		2009
32	Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. ( 19020717 )	Inami K....Hino O.	2008
33	Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. ( 18505086 )	Pryczynicz A....Czyzewska J.	2008
34	Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. ( 17378244 )		2007
35	Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. ( 17003643 )		2006
36	Pancreatic ductal carcinoma: from the bench to the bedside. ( 16998251 )		2006
37	Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. ( 17072983 )	Yekebas EF...Izbicki JR	2006
38	Contrast-enhanced sonography of pancreatic ductal carcinoma using agent detection imaging. ( 27277616 )	Ichino N...Mizoguchi Y	2006
39	Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. ( 16125925 )	Kisanuki H....Mano H.	2005
40	Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. ( 16053509 )	Ishikawa M....Mano H.	2005
41	Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. ( 15951559 )	Kobayashi A....Saisho H.	2005
42	Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. ( 16335935 )	Cecconi D....Righetti P.G.	2005
43	Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? ( 16018800 )	Wada R....Matsumoto M.	2005
44	Factors predicting recurrence after resection of pancreatic ductal carcinoma. ( 15968250 )		2005
45	Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. ( 15985168 )		2005
46	Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. ( 16136352 )		2005
47	Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. ( 15084983 )	Ohshima T....Saisho H.	2004
48	Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. ( 14745573 )	GrA1tzmann R....Pilarsky C.	2004
49	A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. ( 15258755 )	Monti P....Piemonti L.	2004
50	Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. ( 14707723 )	Tepel J....Kalthoff H.	2004

Sources

Genes for Pancreatic Ductal Carcinoma

Genes related to Pancreatic Ductal Carcinoma (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	27.95	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16018800
2	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	27.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14681945 15725805
3	KRT7	Keratin 7	Protein Coding	27.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7513668 12817878 15725805
4	KRT20	Keratin 20	Protein Coding	26.91	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15725805
5	TYMP	Thymidine Phosphorylase	Protein Coding	24.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12717266 11391857
6	SMAD4	SMAD Family Member 4	Protein Coding	22.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11431719 11391801 15084978 (more) 11787853
7	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	22.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	TGM2	Transglutaminase 2	Protein Coding	21.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	16951195
9	TP53	Tumor Protein P53	Protein Coding	20.89	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	20.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	20.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Pancreatic Ductal Carcinoma

Sources

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Sources

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 20)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.63	CDKN2A SMAD4 TP53 VEGFA
2	Pathways in cancer ³⁷	12.59	CDKN2A SMAD4 TP53 VEGFA
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.46	CDKN2A MUC2 SMAD4 TP53
4	O-linked glycosylation ⁶⁶ Show member pathways O-linked glycosylation of mucins ⁶⁶	12.01	MUC1 MUC2 MUC6
5	Colorectal Cancer Metastasis ⁶⁴	11.95	SMAD4 TP53 VEGFA
6	Integrated Breast Cancer Pathway ¹	11.87	SMAD4 TP53 VEGFA
7	Diseases of glycosylation ⁶⁶ Show member pathways Diseases associated with O-glycosylation of proteins ⁶⁶	11.82	MUC1 MUC2 MUC6
8	DNA Damage Response (only ATM dependent) ¹	11.69	CDKN2A SMAD4 TP53
9	Interleukin-4 and 13 signaling ⁶⁶	11.67	MUC1 TP53 VEGFA
10	Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) ⁶⁶ Show member pathways Dectin-2 family ⁶⁶ Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) ⁶⁶ Defective GALNT12 causes colorectal cancer 1 (CRCS1) ⁶⁶ Termination of O-glycan biosynthesis ⁶⁶	11.62	MUC1 MUC2 MUC6
11	Senescence and Autophagy in Cancer ¹	11.57	CDKN2A SMAD4 TP53
12	SMAD Signaling Network ⁶⁴	11.54	CDKN2A SMAD4 TP53 VEGFA
13	HIF1Alpha Pathway ⁶⁴	11.23	CDKN2A TP53 VEGFA
14	Hepatitis C and Hepatocellular Carcinoma ¹	11.14	SMAD4 TP53 VEGFA
15	Oncogene Induced Senescence ⁶⁶	11.1	CDKN2A TP53
16	Transcription_P53 signaling pathway ²²	10.99	CDKN2A SMAD4 TP53 VEGFA
17	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁴	10.89	CDKN2A TP53
18	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.88	CDKN2A TP53
19	NTHi-Induced Signaling ⁶⁴	10.85	MUC2 SMAD4
20	Bladder cancer ³⁷ ¹	10.79	CDKN2A TP53 TYMP VEGFA

Sources

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	Golgi lumen	GO:0005796	8.8	MUC1 MUC2 MUC6

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell growth	GO:0030308	9.54	CDKN2A SMAD4 TP53
2	maintenance of gastrointestinal epithelium	GO:0030277	9.32	MUC2 MUC6
3	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.26	MUC1 TP53
4	replicative senescence	GO:0090399	9.16	CDKN2A TP53
5	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.13	MUC1 MUC2 MUC6
6	O-glycan processing	GO:0016266	8.8	MUC1 MUC2 MUC6

Sources

Sources for Pancreatic Ductal Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Pancreatic Ductal Carcinoma

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Classifications:

External Ids:

Summaries for Pancreatic Ductal Carcinoma

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

Genes for Pancreatic Ductal Carcinoma

Genes related to Pancreatic Ductal Carcinoma (0 elite genes):

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

Sources for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :